Regenerative Medicine and Dentistry (RMD) is announcing a Call for Papers for the topic “Stem Cell Engineering, Organoids, and Cell-Free Therapies”.

Stem cell engineering, organoid technology, and cell-free therapeutic strategies are collectively redefining the boundaries of regenerative medicine. Stem cell-derived constructs now offer unprecedented control over cellular identity and tissue fate, while organoids recapitulate the multicellular complexity of human organs with remarkable fidelity. In parallel, cell-free approaches, encompassing extracellular vesicles, exosomes, secretome-based interventions, and acellular biomaterials, are emerging as potent, scalable alternatives that circumvent the translational barriers associated with live-cell therapies. To capture the extraordinary momentum across these converging fields, our journal is pleased to announce a Call for Papers on Stem Cell Engineering, Organoids, and Cell-Free Therapies.

This Call for Papers seeks to consolidate the most rigorous, high-impact research at the intersection of stem cell biology, three-dimensional tissue modeling, and cell-free regenerative strategies. The journal aspires to build a definitive reference collection that bridges fundamental discovery with clinical application, offering a platform where developmental biologists, bioengineers, and translational scientists can share transformative findings and shape the future of restorative medicine.

We warmly welcome original research articles, comprehensive reviews, and forward-looking perspectives that demonstrate methodological innovation, mechanistic depth, and tangible potential for improving patient outcomes.

Topics of particular interest include (but are not limited to):

- Engineering strategies for directing stem cell fate and enhancing therapeutic potency;

- Organoid construction with advanced vascularization, innervation, and immune integration;

- Cell-free modalities including exosomes, extracellular vesicles, and secretome-based therapies;

- Scalable biofabrication and bioprocessing platforms for clinical translation;

- Disease modeling, drug screening, and personalized medicine applications.

Academic Editor:

Assoc. Prof. Long Bai
Shanghai University

Prof. Akon Higuchi
Wenzhou Medical University

Dr. Lan Xiao
Griffith University

Submission deadline: 31 October 2026
Office Contact: rmd@sciltp.com
Instruction for Authors: https://www.sciltp.com/journals/rmd/instructionForAuthors
Submission Link: https://sciflux.org/authors/submissions

All manuscripts will undergo peer review in accordance with the journal’s established policies and procedures. Final acceptance will be based on the peer-review reports and the evaluation of the Academic Editors and the Editor-in-Chief. Decisions will be made by the Editor-in-Chief or Academic Editors who have no conflicts of interest with any of the authors.